Appendix 4E and 2025 Annual Report
Released
Released
Announcement PDF
Tetratherix Limited
Appendix 4E
Preliminary final report
1. Company details
Name of entity:
ABN:
Reporting period:
Previous period:
Tetratherix Limited
72 607 771 077
For the year ended 30 June 2025
For the year ended 30 June 2024
2. Results for announcement to the market
$
Revenues from ordinary activities
up
32.3% to
1,142,646
Underlying loss for the year1
up
78.8% to
(4,554,851)
Loss from ordinary activities after tax attributable to the owners of
Tetratherix Limited
up
269.1% to
(9,425,552)
Loss for the year attributable to the owners of Tetratherix Limited
up
269.1% to
(9,425,552)
Dividends
There were no dividends paid, recommended or declared during the current or previous financial period.
Comments
The loss for the Consolidated Entity after providing for income tax amounted to $9,425,552 (30 June 2024: $2,553,976).
1Underlying loss represents statutory loss for the year adjusted for non-recurring non-operating items.
Refer to the Financial Overview section of the 2025 Annual Report for further information, including a reconciliation between
net loss before tax and underlying loss for the year.
3. Net tangible assets
Reporting
period
Cents
Net tangible assets per ordinary security
0.05
4. Control gained over entities
On 3 April 2025, Tetratherix BTX Pty Ltd (a wholly owned subsidiary of the parent entity) was incorporated.
5. Loss of control over entities
Not applicable.
Previous
period
Cents
(18.11)
Tetratherix Limited
Appendix 4E
Preliminary final report
6. Dividends
Current period
There were no dividends paid, recommended or declared during the current financial period.
Previous period
There were no dividends paid, recommended or declared during the previous financial period.
7. Details of associates and joint venture entities
Reporting entity's
percentage holding
Reporting
period
%
Name of associate / joint venture
Tutelix Pty Ltd
50.00%
8. Audit qualification or review
Details of audit/review dispute or qualification (if any):
The financial statements have been audited and an unmodified opinion has been issued.
9. Attachments
Details of attachments (if any):
The Annual Report of Tetratherix Limited for the year ended 30 June 2025 is attached.
10. Signed
Signed
William Knox
Director
Sydney
Date: 28 August 2025
Previous
period
%
50.00%
Annual Report
2025
Tetratherix Limited
ACN 607 771 077
ASX:TTX
Tetratherix Limited (ASX:TTX) Annual Report 2025
2
Table of Contents
Year In Review ����������������������������������������������������������������������������������������������������������������������������������������3
1. Our Company �������������������������������������������������������������������������������������������������������������������� 5
About Tetratherix �����������������������������������������������������������������������������������������������������������������������������������6
Tetratherix at a Glance �������������������������������������������������������������������������������������������������������������������������8
Why Does the World Need Tetratherix? ��������������������������������������������������������������������������������������������9
Tetramatrix™ Platform Technology���������������������������������������������������������������������������������������������������9
Tetratherix Franchises ������������������������������������������������������������������������������������������������������������������������� 10
Bone Regeneration-Dental (Tegenix) ���������������������������������������������������������������������������������������� 12
Bone Regeneration-Ortho (TegenEOS)������������������������������������������������������������������������������������� 13
Tissue Spacing-Oncology (Tutelix) ��������������������������������������������������������������������������������������������� 14
Tissue Spacing-Ophthalmic (Optelex) ��������������������������������������������������������������������������������������� 15
Tissue Healing-Scar Reduction (TetraDerm) ��������������������������������������������������������������������������� 16
2. Directors Report �������������������������������������������������������������������������������������������������������������� 17
Operating Review �������������������������������������������������������������������������������������������������������������������������������� 18
Our Strategy...................................................................................................................................... 19
Our FY25 Highlights ����������������������������������������������������������������������������������������������������������������������� 20
Our FY26 Deliverables�������������������������������������������������������������������������������������������������������������������� 21
Financial Overview �����������������������������������������������������������������������������������������������������������������������������22
Profit and Loss ����������������������������������������������������������������������������������������������������������������������������������23
Cashflow............................................................................................................................................ 26
Statement of Financial Position ����������������������������������������������������������������������������������������������������27
Governance and Risk ������������������������������������������������������������������������������������������������������������������������� 28
Risks.................................................................................................................................................... 29
Governance.......................................................................................................................................33
Directors Information.......................................................................................................................... 36
Directors’ Profiles................................................................................................................................. 39
Joint Company Secretary.................................................................................................................... 41
Group Executive Team.........................................................................................................................42
Remuneration Report (Audited) ����������������������������������������������������������������������������������������������������� 43
3. Auditor’s Independence Declaration ���������������������������������������������������������������������������51
4. Financial Report ������������������������������������������������������������������������������������������������������������� 53
Financial Statements........................................................................................................................... 55
Notes to the Financial Statements................................................................................................... 59
Consolidated Entity Disclosure Statement..................................................................................... 95
Directors Declaration.......................................................................................................................... 96
Independent Auditor’s Report to the Members of Tetratherix Limited ���������������������������������� 97
5. Additional Information................................................................................................. 100
Shareholder Information ������������������������������������������������������������������������������������������������������������������101
Corporate Directory ��������������������������������������������������������������������������������������������������������������������������105
Year in Review
Tetratherix Limited (ASX:TTX) Annual Report 2025
3
Year in Review
Dear Shareholders,
It is with great pleasure that we present the Annual Report for Tetratherix Ltd for
the financial year ended June 30, 2025. This year has been a period of remarkable
progress and strategic development, laying a strong foundation for our future.
We have achieved significant milestones and have also strengthened our
organisational core to ensure long-term, sustainable growth.
Emma Cleary
Non-Executive Chair
Our financial year 2025 was marked by pivotal achievements on a number of
fronts including successfully listing on the ASX, inventing an entirely new polymer
upon our platform, executing our Master Services Agreement (MSA) with Henry
Schein and licencing agreement with BioOptix, completion of three FDA presubmission meetings within our Bone Regeneration (Tegenix) and Tissue Spacing
(Tutelix) franchises, as well as completion of our Pod design and equipment
procurement for our production scale up. Collectively these achievements are a
powerful validation of our innovative work and will be instrumental in accelerating
our commercialisation plans across our three key franchises, whilst continuing to
develop our R&D pipeline. It is a testament to the hard work and dedication of our
entire team and a clear signal of confidence from key stakeholders in our mission.
Internally, we have continued to focus on building a high-performing and
dynamic executive team including the appointment of Cherie Beach as our new
Chief Financial Officer. Cherie brings a wealth of experience and strong financial
acumen that will be invaluable as we navigate our next phase of growth. She joins
our exceptional leadership team, which includes Will Knox (Executive Director and
CEO), Ali Fathi (Founder, Executive Director and CTO) and Terence Abrams (CoFounder and COO). This team’s collective expertise and passion are the driving
force behind our success.
William Knox
Executive Director and CEO
To support our growth, we have invested in developing strong governance controls
and in building out our staff offering. Our corporate values guide our decisions
and foster a collaborative and ethical culture. These values—Innovation, Humility,
Collaboration, and Curiosity—define who we are and ensure we remain a trusted
and responsible leader in our field. We believe that by living these values every
day, we not only attract and retain top talent but also earn the confidence of our
partners and shareholders as we continue to innovate, develop and commercialise
our IP. At the core of everything we do is our focus on our clinical experts, their
patients and our absolute passion to improve clinical outcomes.
As we move into FY26, we have secured a substantial Australian Government
Industry Growth Program (IGP) Grant for $3.3 million. Additionally, we have
implemented a new incentive plan to attract and retain talent, and most
recently signed a lease agreement for a new facility to facilitate our advanced
manufacturing capability.
Our key objectives for the 2026 financial year are clear and ambitious:
•
Continue to develop products across our three key franchises and
specifically achieve first in-human trials for Tutelix, FDA 510(k) clearance
for both TegenEOS and Tegenix and commence cohort 3 clinical trials for
Tetraderm.
•
Focus on advancing our partner strategic alliances to accelerate growth in
global markets.
•
Continue to build high performing teams by attracting home grown talent.
•
Build world class manufacturing facilities to support the future growth of
the company.
•
Ensuring sustainable long term growth through appropriately funded R&D
activities and continued strong financial control.
Year in Review
Tetratherix Limited (ASX:TTX) Annual Report 2025
4
We would like to express our gratitude to our entire team, whose dedication
makes these achievements possible. We also want to thank our partners and our
shareholders for their continued support and belief in our vision. We are excited
about the journey ahead and remain committed to unlocking new possibilities in
the life sciences sector. We remain focused on our mission to develop products
upon our platform technology to expand healthcare access by treating more
patients outside traditional hospital and surgical settings, fostering greater
global health equity and improving clinical outcomes.
Yours sincerely,
Will and Emma
IPO launch on the ASX (30/06/25)
Tetratherix Limited (ASX:TTX) Annual Report 2025
1.
Our
Company
5
Our Company
Tetratherix Limited (ASX:TTX) Annual Report 2025
About Tetratherix
We are an Australian biomedical technology company, founded in 2015 as an advanced manufacturing and intellectual
property generating entity in the biomaterial and regenerative medicine space. At our core, we have our flagship
Tetramatrix™ platform technology.
We aim to commercialise multiple products, derived from our Tetramatrix™ platform technology through a flywheel model
in which our established foundational intellectual property, safety, efficacy, and streamlined manufacturing processes will
facilitate rapid and efficient development of products in different fields of medicine.
Our flywheel in motion to use Tetramatrix™ to derive multiple products
in three franchises
model
in motion
S
H
P
Advanced Manufacturing
Intellectual Property
Safety and Performance
Established manufacturing
in Sydney governed by an
ISO13485:2016 certified quality
management system. TTX will
manufacture finished goods at
scale for partners.
The Company currently has a total
of 36 registered patents in USA,
Australia, Japan, China and major
markets in Europe, as well as an
additional 18 published patents and
2 pending patent applications.
We have explored the safety
and efficacy of the platform in 3
separate clinical trials enrolling
>20 patients, as well as multiple
preclinical animal models.
6
Our Company
Tetratherix Limited (ASX:TTX) Annual Report 2025
7
Our Mission
We use the Tetramatrix™ to develop
multiple products multiple products
to treat patients faster, cheaper and
safer.
Our goal is to derive products from
our platform technology to expand
healthcare access by treating more
patients outside traditional hospital
and surgical settings, fostering
greater health equity worldwide and
improving clinical outcomes.
IPO launch on the ASX (30/06/25)
Tetramatrix™ Platform Technology
Intelligent
Modular
Biomimetic
Safe
The material is an injectable
fluid to avoid causing
damage to the body during
its application. Upon
injection, triggered by
physiological temperature,
a 3D matrix is formed that
physically integrates and
adheres to the target tissue.
A biomaterial platform
built with unique polymer
programming akin to
‘medical Lego®’ to form
implantable products
to solve a wide range of
clinical problems.
The matrix has similar water
content and mechanical
properties to natural tissue,
and therefore is impervious
to the body, bridging healthy
and injured tissues, helping
heal injuries or physically
manipulating the body
during surgical interventions.
Due to the unique polymer
programming of the
material, once the matrix
serves its purpose, the
material gradually and
safely bioresorbs in the
body with no impact locally
or systemically.
Our Company
Tetratherix Limited (ASX:TTX) Annual Report 2025
Tetratherix at a Glance
Technology
3
Operation
Active R&D Projects
POC
Polymers
New chemistries
from a single
Platform
Preclinical
Regulatory
In-market
Regeneration
14
Tissue Space
Research
Groups
Tissue Healing
PNPHO
S
No change to timeline outlined in the prospectus
PPHO
PH2NO
3
12
United States
research
organisations
Unique Proposition
Technical and
translational offering
- Minimally invasive
- Clinically modular
- Scalable
manufacturing
5
Validated Clinical Utility
8
Passed
ISO13485:2016
audits
36 24 2044
Granted
Patents
Countries
People
and Culture
67%
Identified
as Women
Products under
development
- $US 6.8 billion TAM
- Three clinical trials
- Three confirmed
partnerships
China
Cultural Diversity
15
STEM
Graduates
FTE
(Full-Time
Equivalent)
38%
Born
Outside
Australia
Gender Diversity
Expiry
Date
80%
43%
R&D
2
Skill
Australia
Total Underlying
Expenditure1
0
Employee
attrition rate
over 5 years
1
excluding one-offs and non recurring items
2
R&D includes specific projects, directly attributable staff, laboratory costs, trademarks and patents
8
Our Company
Tetratherix Limited (ASX:TTX) Annual Report 2025
9
Why Does the World Need Tetratherix?
The Company’s primary focus is on developing and commercialising the Company’s unique and innovative Tetramatrix™
platform technology. Tetramatrix™ is a platform of proprietary, fully synthetic polymer products that are compatible
with minimally invasive administration techniques and cause minimal foreign body reaction (making it ideal for
regenerative medicine)1.
The evolving dynamics of the global healthcare system is demanding
innovative and cost-effective biomaterials
Trends in healthcare delivery
How does Tetramatrix address the problem?
Rising patient expectations
Minimally invasive delivery
Patients are demanding increasingly higher
quality of care, with a particular focus on
reducing recovery times and lowering risk of
complications (e.g. infection, blood loss, pain) which is also a driver of increasing healthcare
costs for patients and payers.
Water-based solution injected through fine
gauge needles.
Need for cost-effective,
decentralised care
Low cost, scalable production
Increasing global healthcare spending and
demand for healthcare services is necessitating
investment in cost-effective tools and treatments,
including those that can be delivered outside a
traditional hospital setting, to minimise burden on
the healthcare system.
Safe, biocompatible and bioresorbable
No foreign body reaction upon application.
Non-labour intensive, low cost and manufactured
with readily available materials.
Seamlessly integrated into existing
workflows
Delivered via needle with no additional
equipment required.
Tetramatrix™ Platform Technology
The Tetramatrix™ platform technology is clinically modular, integrates and adheres to the target tissue to support different
regenerative biological processes and/or to simplify surgical interventions. The core technology used in Tetramatrix™ is
a family of synthetic polymers comprising of four building blocks that act as medical Lego®, allowing fine tuning of the
polymer chemistry to address different clinical needs.
Three polymer configurations are formulated by using Tetramatrix™; these three polymer configurations share ~95%
chemical similarity, are manufactured with an identical processing conditions and quality management system.
Tetramatrix™ is used to derive products in three market segments, also called franchises that include bone regeneration,
tissue spacing and tissue healing.
Published in three peer-reviewed journal articles: (1) Calder, D. et al. Thermoresponsive and Injectable Hydrogel for Tissue Agnostic Regeneration (Adv.
Healthcare Mater. 23/2022). Adv Healthc Mater 11, 2270137 (2022); (2) Calder, D. et al. Universal Hydrogel Carrier Enhances Bone Graft Success: Preclinical and
Clinical Evaluation. Adv Healthc Mater (2025). doi:10.1002/adhm.202403930; and (3) Fathi, A. et al. Elastin based cell-laden injectable hydrogels with tunable
gelation, mechanical and biodegradation properties. Biomaterials 35, 5425–5435 (2014).
1
Our Company
Tetratherix Limited (ASX:TTX) Annual Report 2025
10
Tetratherix Franchises
The Company has used its Tetramatrix™ to manufacture and provide tailored products in three market franchises: bone
regeneration, tissue spacing and tissue healing.
The total addressable market (TAM) for all biomaterials in these three markets is collectively expected to be US$6.8 billion in
CY2025 and is anticipated to grow to US$9.5 billion by CY2030.
Bone Regeneration
Tissue Spacing
Tissue Healing
Dental
Oncology
Surgical Site Management
Tegenix
Tutelix
TetraDerm
A universal enabling solution
to simplify complex oral and
dental procedures
Safe and easy to use solution
for more effective and simpler
spacing
Intraoperative scar
prevention solution
Orthopaedic
Ophthalmic
TegenEOS
Optelex
A flowable solution
for minimally invasive
applications
Novel Synthetic reversible
Ophthalmic Viscoelastic Device
(OVD) for safe and simple
application
$2.1
TAM bn $US
$1.3
TAM bn $US
$3.4
TAM bn $US
Our Company
Tetratherix Limited (ASX:TTX) Annual Report 2025
Tissue Spacing Franchise
Tutelix
Optelex
Rectal Spacing for oncology
radiation therapy
Ophthalmic viscoelastic
device (OVD)
PPHO
PH2NO
Smart/ thermoresponsive
Smart/ thermoresponsive
Resorbs after 12 weeks
Instant reversible to remove
Radiopaque structure
Transparent structure
Core Technology
Tetramatrix
Adhesive and cohesive
Backbone
Hydrophobic
Hydrophilic
Active Groups
An inert and modular
backbone is used to
design and develop
a flowable and smart
platform from the
ground up.
Hydrophobic groups
are incorporated that
breakdown overtime
by hydrolysis, leading
to resorption of the
platform.
The addition of
hydrophilic units to
the system to make
the smart platform
water based to ensure
clinical utility.
Optional group to
be able to ionically
interact with the
host tissue to
ensure anatomical
adhesiveness of matrix.
PNPHO
Smart/ thermoresponsive
White structure in body
Resorbs after 4 to 8 weeks
Adhesive
Bone Regeneration Franchise
Tissue Healing Franchise
Tegenix
TegenEOS
TetraDerm
Dental
bone graft
extender
Orthopaedic
bone graft
extender
Intraoperative solution
to reduce scar formation
after surgeries
11
Our Company
Tetratherix Limited (ASX:TTX) Annual Report 2025
12
Bone Regeneration-Dental (Tegenix)
The product is indicated for use as a bone graft extender, to be mixed with different allografts, autologous bone products
and synthetic grafts for dental and oral applications. The product under development for this application is called Tegenix,
which is a 1ml solution, consisting of 280 mg/ml of PNPHO polymer that is dissolved in phosphate buffered saline (PBS).
Tegenix is provided sterile in a syringe to be used by clinicians at the point of care. The unique proposition of Tegenix is to
disrupt the market by driving innovation that streamlines the clinical process, reduces costs and enhances patient outcomes.
1 cc solutions
280 mg/ml of PNPHO
Mouldable and
shapable putty
Gentle press-fit into the site and
adherence without primary closure
In situ
Mixing
Press-fit
Amenable to different graft
particles and easy to mix
Easy to handle and easy to
manipulate
Adhesive putty that
supports natural healing
Modular and Flexible
Simplify Complex Procedures
Support Natural Healing
A carrier system for any and every type
of bone graft to form mouldable and
shapable composites for easy and gentle
delivery, which preserves the integrity of
the host tissue for faster healing.
Adhesive plug that negates the need
for primary closure and/or membranes
which reduces the cost, and simplifies
surgical procedures, including guided bone
regeneration.
The matrix maintains the bone graft in
3D geometry to allow cellular ingrowth
and integration within the composite.
The biocompatible nature of the hydrogel
works synergistically with any graft,
supporting natural healing.
FY25 Updates
Executed Master Agreement
with Henry Schein*
Project on
track for 510(k)
clearance in
FY26
Jul-24
Jun-25
FDA Pre-submission
meetings**
Initiated FDA preclinical with NAMSA
NOTES: * Tetratherix executed a Master Agreement with Henry Schein, a global market leader in dental surgeries, for global commercialisation of
Tegenix with the initial focus on the US market.
** Multiple FDA Pre-submission meetings were successfully completed during which, as recent as May 2025, FDA representatives remain
unchanged, and the meetings continued to be very productive.
Our Company
Tetratherix Limited (ASX:TTX) Annual Report 2025
13
Bone Regeneration-Ortho (TegenEOS)
The product is indicated for use as a bone graft extender to be mixed with different allograft and autologous bone
particles for orthopaedic applications. The product under development for this application is called TegenEOS, which is a
3ml solution consisting of 280 mg/ml of PNPHO polymer that is dissolved in phosphate buffered saline (PBS). As such, the
chemical composition of Tegenix and TegenEOS are identical and the only difference is the product volume.
2 cc solutions
280 mg/ml of PNPHO
Flowable mixture of
TegenEOS and bone
graft material
Fills the void and keeps
grafts geometrically
in place
TegenEOS resorbs
allowing cell and blood
vessel ingrowth
Outcome: Expedited
healing
Easy to handle and apply in
minimally invasive scenarios
Stabilises the bone graft
resulting in better outcomes
Reduces the amount
of bone graft required
Once mixed with bone grafts, the resulting
mixture is flowable for ease of delivery for
trauma surgeries and spinal cage delivery
(including injectable applications).
The bone graft particles are kept in a 3D
manner at the intended sites, allowing
cellular ingrowth for a more effective
cell-activation/ osteoinductivity, leading to
faster healing.
The carrier system reduces the requirement
for the amount of bone grafts and thus
increases production throughputs for the
partners from defined number of human
donors.
FY25 Updates
Regulatory pathway defined
through US-consultant*
Project on
track for 510(k)
clearance in
FY26
Jul-24
Jun-25
Designed preclinical
FDA studies under GLP
Progressed commercial
partnership
NOTES: * Defined regulatory pathway with our US-based, experienced regulatory consultants.
Our Company
Tetratherix Limited (ASX:TTX) Annual Report 2025
14
Tissue Spacing-Oncology (Tutelix)
The product is indicated for use by urologists to generate space between the prostate and rectum to reduce radiation
therapy side effects. The product under development for this application is called Tutelix, which is a 15 ml solution consisting
of 150 mg/ml of PPHO dissolved in PBS with 160 mg I/ml iohexol. Tutelix is an injectable and radiopaque solution that forms
hydrogel and generates space to reduce radiation side effects during prostate oncology radiation. TTX formed a Joint
Venture (JV), Tutelix Pty Ltd to expedite the commercialisation of the product for this indication. Tetratherix currently holds
50% equity in Tutelix.
15 cc solutions
150 mg/ml PPHO
+ Iohexol
Space generation
to reduce side
effects to rectum
during radiation
Injection to the
space between
prostate/ rectum
Procedure Optionality
Simple to adjust (+/- volume)
A water-based solution makes the
product amenable to single injection after
hydrodissection OR as multiple gradual
injections, two commonly used techniques.
Activated organically by body temperature,
the solution transitions into a hydrogel.
The hydrogel is smooth, flowable and can
be immediately reversed with cold-saline.
The hydrogel breaks down to non-toxic
components and bioresorbs within 3 to 6
months completely.
FY25 Updates
HREC approval for AU
Clinical trial
Visible to physicians under
both CT-scan and ultrasound
In contrast to incumbent products, the
product is visible under Computed
Tomography without enhancement
which allows for a safer, simpler, more
accurate and cost-effective outcome when
delivering radiotherapy.
Project on
track for
First Human
Implantation
(H1 FY26)**
Jul-24
Jun-25
Product optimisation
in porcine studies*
FDA Pre-submission
meeting
NOTES: * Tutelix Pty Ltd finalised its ~$2 million capital raise via issuing SAFE notes at a valuation cap of $20m. Investors in Tutelix Pty Ltd mainly
involves angel investors and key opinion leaders in the field of radiation oncology and urology. Using the raised capital, Tutelix Pty Ltd, successfully
completed two porcine animal studies to confirm the safety and performance of the product to generate space between prostate and rectum.
** Tutelix 510(k) clearance is expected in FY28, as previously outlined. Commercially, Tutelix will disrupt the emerging spacing market by bringing a
superior urology product to market and extending to other critical indications.
Our Company
Tetratherix Limited (ASX:TTX) Annual Report 2025
Tissue Spacing-Ophthalmic (Optelex)
The product is indicated for use intraoperatively as an ophthalmic viscoelastic devices (OVD) to maintain the volume of
the eye anterior chamber during any eye surgery. The product under development for this application is called Optelex.
The product is 1ml solution of our most recent polymer formulations, PH2O and PH2NO, developed by optimising our core
Tetramatrix™ platform technology to form cohesive and adhesive transparent OVD products. Tetratherix has entered into
a licensing agreement with an American company, BioOptix Inc to develop the OVD product and Tetratherix holds 12.5%
equity in this company.
Transparent structure that
remains within the eye
during surgeries
Reverse gelation by using
cold saline to wash product
residues
1 cc solution*
Synthetic
Not animal-derived
Low cost and scaled
manufacturing
Easy to remove and reduces
known side effects
The product is fully synthetic and there
is no animal derived component used in
the product, which provides supply chain
security to the partner.
Low cost of goods, scalable production
and controlled sterility and endotoxins
provide commercially attractive unit
economics.
The product’s instant dissolution by
lowering the temperature of the site via
cold saline, allows easy and fast removal
of the product after the completion of the
surgery.
FY25 Updates
New provisional
patent submission*
Project on
track
Jul-24
Jun-25
New polymer
invention
Executed Licensing
Agreement with BioOptix**
NOTES: * A new composition of matter Australian provisional patent application has been lodged to cover the chemical composition of the invention
and its application and therefore, details will be provided i
Share your feedback
Discover